Skip to main content
Louis Brenner, MD, Nephrology, Boston, MA

LouisBrennerMD

Nephrology Boston, MA

Chronic Renal Failure & Dialysis, Hereditary Kidney Disease Genetics

Lecturer on Medicine, Brigham and Women's Hospital

Dr. Brenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Brenner's full profile

Already have an account?

  • Office

    Brigham Womens Hospital
    75 Francis Street
    Boston, MA 02115
    Phone+1 617-732-6660

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital
    Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1999 - 2002
  • Brigham and Women's Hospital
    Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1996

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Publications & Presentations

PubMed

Press Mentions

  • Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop
    Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria WorkshopJune 21st, 2019
  • Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. To Board of Directors
    Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. To Board of DirectorsOctober 17th, 2017
  • Die Europäische Kommission Erteilt Der Studientherapie Von Allena Pharmaceuticals Zur Behandlung Primärer Hyperoxalurie Den Orphan-Drug-Status
    Die Europäische Kommission Erteilt Der Studientherapie Von Allena Pharmaceuticals Zur Behandlung Primärer Hyperoxalurie Den Orphan-Drug-StatusJuly 27th, 2017
  • Join now to see all

Professional Memberships